Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) saw a 211.8% surge last week, reaching an all-time high after positive clinical trial results for eczema treatment. The stock hit $26.95 on Friday but closed at $25.10, down 1.65%. The drug showed a 72% reduction in eczema severity compared to a 40% reduction with a placebo.

The therapy was well-tolerated and more effective with prolonged use, leading to plans for a Phase 2 trial in the first quarter of 2026. The trial will enroll 200 patients with moderate-to-severe eczema, testing different doses of soquelitinib for 12 weeks with a 30-day follow-up period.

While CRVS shows investment potential, some believe AI stocks offer greater returns with less risk. For those interested in an inexpensive AI stock benefiting from tariffs and onshoring, a report on the best short-term AI stock is available.

Read more at Yahoo Finance: Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study